NEW! The M65-ELISA assay has been independently validated to be used as a biomarker in early clinical development of a XIAP antisense compound (Cummings et al., 2006). Both the M30-Apoptosense^® and M65-ELISA assays are now independently validated (Cummings et al., 2005).

NEW! M30-Apoptosense^® and M65 ELISA assays were used for non-invasive monitoring of prostate cancer treatment. The superior clinical efficiency of docetaxel treatment was reflected in increased levels of the epithelial apoptosis biomarker in blood samples (Kramer et al., 2006).

NEW! M30-Apoptosense^® ELISA can be used to predict which patients with chronic hepatitis C virus (HCV) infection that will respond to antiviral therapy (Volkmann et al., 2006).

NEW! Determination of hepatocyte caspase activation in the blood using the M30-Apoptosense^® ELISA is a predictor of nonalcoholic fatty liver disease in human subjects (Wieckowska et al., 2006).

NEW! Demonstration of endothelial cell apoptosis in the blood of patients infected with hantaviruses (Klingström et al., 2006).